Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates

Nawal Al Kaabi(Khalifa University of Science and Technology), Abderrahim Oulhaj(Khalifa University of Science and Technology), Subhashini Ganesan, Farida Ismail Al Hosani(Abu Dhabi University), Omer Najim, Halah Ibrahim(Khalifa University of Science and Technology), Juan Acuña(Khalifa University of Science and Technology), Ahmed R. Alsuwaidi(United Arab Emirates University), Ashraf Kamour(Shaikh Khalifa Medical City), Ashraf Alzaabi(United Arab Emirates University), Badreyya Ahmed Al Shehhi(Abu Dhabi University), Habiba Al Safar(Khalifa University of Science and Technology), Salah Eldin Hussein(Shaikh Khalifa Medical City), Jehad Saleh Abdalla(Shaikh Khalifa Medical City), Dalal Saeed Naser Al Mansoori(Tawam Hospital), Ahmed Abdul Kareem Al Hammadi(Tawam Hospital), Mohammed A. Amari(Shaikh Khalifa Medical City), Ahmed Khamis Al Romaithi(Shaikh Khalifa Medical City), Stefan Weber, Santosh Elavalli, Islam Eltantawy, Noura Khamis Alghaithi(Abu Dhabi Health Services), Jumana Nafiz Al Azazi(Abu Dhabi Health Services), Stephen Geoffrey Holt, Mohamed Mostafa(Clinical Research Organization), Rabih Halwani(University of Sharjah), Hanif Khalak, Wael Elamin, Rami Beiram(United Arab Emirates University), Walid Zaher(Khalifa University of Science and Technology)
Nature Communications
June 9, 2022
10.1038/s41467-022-30835-1
Cited by 36Open Access
Full Text

Abstract

The effectiveness of the inactivated BBIBP-CorV vaccine against severe COVID-19 outcomes (hospitalization, critical care admission and death due to COVID-19) and its long-term effectiveness have not been well characterized among the general population. We conducted a retrospective cohort study using electronic health records of 3,147,869 adults, of which 1,099,886 vaccinated individuals were matched, in a 1:1 ratio to 1,099,886 unvaccinated persons. A Cox-proportional hazard model with time varying coefficients was used to assess the vaccine effectiveness adjusting for age, sex, comorbidity, ethnicity, and the calendar month of entry into the study. Our analysis showed that the effectiveness was 79.6% (95% CI, 77.7 to 81.3) against hospitalization, 86% (95% CI, 82.2 to 89.0) against critical care admission, and 84.1% (95% CI, 70.8 to 91.3) against death due to COVID-19. The effectiveness against these severe outcomes declined over time indicating the need for booster doses to increase protection against severe COVID-19 outcomes.

Related Papers

No related papers found

Powered by citation graph analysis